Copyright
©The Author(s) 2024.
World J Psychiatry. Jan 19, 2024; 14(1): 88-101
Published online Jan 19, 2024. doi: 10.5498/wjp.v14.i1.88
Published online Jan 19, 2024. doi: 10.5498/wjp.v14.i1.88
Table 1 Details of the genome-wide association studies consortiums
Variable | Ancestry | Ref. | Sample size | Sex | Data download |
Metabolite | European | Shin et al[20], 2014 | 7824 | Mixed | http://metabolomics.helmholtz-muenchen.de/gwas/ |
Autism spectrum disorder | European | Grove et al[21], 2017 | Cases = 18381; Controls = 27969 | Mixed | https://doi.org/10.6084/m9.figshare.14671989 |
Table 2 Nominally significant results of the inverse variance weighted method
ID | Metabolite | Outcome | SNP, n | β | SE | P value |
M02137 | Biliverdin | ASD | 3 | -0.255 | 0.122 | 0.038 |
M20675 | 1,5-Anhydroglucitol | ASD | 5 | -0.881 | 0.407 | 0.031 |
M32412 | Butyrylcarnitine | ASD | 12 | -0.219 | 0.111 | 0.049 |
M32497 | 10-undecenoate (11:1n1) | ASD | 3 | 0.546 | 0.258 | 0.034 |
M32847 | X-11530 | ASD | 3 | -0.302 | 0.125 | 0.016 |
M33137 | X-11792 | ASD | 3 | 0.388 | 0.093 | 3.03 × 10-5 |
M33138 | Oxidized bilirubin | ASD | 3 | -0.318 | 0.148 | 0.032 |
M34306 | X-12696 | ASD | 4 | -0.831 | 0.325 | 0.011 |
M34407 | Isovalerylcarnitine | ASD | 4 | -0.976 | 0.393 | 0.013 |
M34420 | Des-Arg(9) bradykinin | ASD | 3 | 0.262 | 0.064 | 4.64 × 10-5 |
M36131 | Alpha-glutamyltyrosine | ASD | 3 | -0.619 | 0.213 | 0.004 |
Table 3 Heterogeneity and pleiotropy tests of the 8 metabolites
Metabolite | Heterogeneity, MR Egger P value | Heterogeneity, IVW P value | Pleiotropy, P value |
Biliverdin | 0.392 | 0.415 | 0.496 |
1,5-anhydroglucitol | 0.482 | 0.034 | 0.067 |
Butyrylcarnitine | 0.174 | 0.007 | 0.016 |
10-Undecenoate (11:1n1) | 0.844 | 0.689 | 0.556 |
Oxidized bilirubin | 0.271 | 0.385 | 0.586 |
Isovalerylcarnitine | 0.030 | 0.058 | 0.744 |
Des-Arg(9) bradykinin | 0.663 | 0.906 | 0.949 |
Alpha-glutamyltyrosine | 0.785 | 0.923 | 0.817 |
Table 4 Top 10 predicted targets of Des-Arg(9)-bradykinin in SwissTargetPrediction
Target | Common name | Target class | Probability |
Bradykinin B1 receptor | BDKRB1 | Family A G protein-coupled receptor | 0.420 |
Neurotensin receptor 1 | NTSR1 | Family A G protein-coupled receptor | 0.189 |
Thrombin | F2 | Protease | 0.169 |
HLA class I histocompatibility antigen A-3 | HLA-A | Surface antigen | 0.140 |
Mu opioid receptor | OPRM1 | Family A G protein-coupled receptor | 0.131 |
Delta opioid receptor | OPRD1 | Family A G protein-coupled receptor | 0.131 |
Kappa opioid receptor | OPRK1 | Family A G protein-coupled receptor | 0.122 |
Neurotensin receptor 2 | NTSR2 | Family A G protein-coupled receptor | 0.122 |
HLA class II histocompatibility antigen DRB3-1 | HLA-DRB3 | Surface antigen | 0.122 |
Cyclin-dependent kinase 2/cyclin A | CDK2, CCNA1, CCNA2 | Other cytosolic protein | 0.122 |
- Citation: Huang ZY, Lyu ZP, Li HG, You HZ, Yang XN, Cha CH. Des-Arg(9) bradykinin as a causal metabolite for autism spectrum disorder. World J Psychiatry 2024; 14(1): 88-101
- URL: https://www.wjgnet.com/2220-3206/full/v14/i1/88.htm
- DOI: https://dx.doi.org/10.5498/wjp.v14.i1.88